Evidence map›Paper›PMID 36628058›Full record

ArticleOpen forum infectious diseases2023

Immune-Based Therapy for Hospitalized Patients With COVID-19 and Risk of Secondary Infections: A Systematic Review and Meta-analysis.

Dima Kabbani, Ashlesha Sonpar, Benson Weyant, Keith C K Lau, Mark Robbins, Sandra Campbell, Karen Doucette, Juan G Abraldes, Tamara Lotfi, Marlene Chaktoura and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Dima KabbaniDepartment of Internal Medicine, American University of Beirut, Beirut, Lebanon.
Ashlesha SonparDepartment of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Benson WeyantDepartment of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Keith C K LauDepartment of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Mark RobbinsDepartment of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Sandra CampbellJohn W. Scott Health Sciences Library, University of Alberta, Edmonton, Canada.
Karen DoucetteDepartment of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Juan G AbraldesDepartment of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Tamara LotfiDepartment of Health Research Methods, Evidence, and Impact (HEI), McMaster University, Hamilton, Ontario, Canada.
Marlene ChaktouraDepartment of Internal Medicine, American University of Beirut, Beirut, Lebanon.
Elie A AklDepartment of Internal Medicine, American University of Beirut, Beirut, Lebanon.
Carlos CerveraDepartment of Medicine, University of Alberta, Edmonton, Alberta, Canada.
University of Alberta · CAMcMaster University · CAAmerican University of Beirut · LB

Funding

Genetic and Metabolic Determinants of 25(OH)D levels at Baseline and One Year: Findings from a Dose Ranging Vitamin D trialD43TW009118 · FIC · AMERICAN UNIVERSITY OF BEIRUT · PI FULEIHAN, GHADA ELHAJJ · 2012 to 2024
$2.5M
FIC NIH HHS D43 TW009118
6 · The paper itself

Abstract

Background: Immune-based therapies are standard-of-care treatment for coronavirus disease 2019 (COVID-19) patients requiring hospitalization. However, safety concerns related to the potential risk of secondary infections may limit their use. Methods: We searched OVID Medline, Ovid EMBASE, SCOPUS, Cochrane Library, clinicaltrials.gov, and PROSPERO in October 2020 and updated the search in November 2021. We included randomized controlled trials (RCTs). Pairs of reviewers screened abstracts and full studies and extracted data in an independent manner. We used RevMan to conduct a meta-analysis using random-effects models to calculate the pooled risk ratio (RR) and 95% CI for the incidence of infection. Statistical heterogeneity was determined using the Results: This was a meta-analysis of 37 RCTs including 32 621 participants (mean age, 60 years; 64% male). The use of immune-based therapy for COVID-19 conferred mild protection for the occurrence of secondary infections (711/15 721, 4.5%, vs 616/16 900, 3.6%; RR, 0.82; 95% CI, 0.71-0.95; Conclusions: We identified moderate-certainty evidence that the use of immune-based therapies in COVID-19 requiring hospitalization does not increase the risk of secondary infections.

Indexed as

COVID-19immunotherapysecondary infection

Identifiers

PMID36628058
PMCPMC9825199
OpenAlexW4311830497

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.